LU91039I2 - Proteq flu and its pharmaceutically acceptable derivatives - Google Patents
Proteq flu and its pharmaceutically acceptable derivativesInfo
- Publication number
- LU91039I2 LU91039I2 LU91039C LU91039C LU91039I2 LU 91039 I2 LU91039 I2 LU 91039I2 LU 91039 C LU91039 C LU 91039C LU 91039 C LU91039 C LU 91039C LU 91039 I2 LU91039 I2 LU 91039I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- proteq
- flu
- pharmaceutically acceptable
- acceptable derivatives
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9071187A | 1987-08-28 | 1987-08-28 | |
US11033587A | 1987-10-20 | 1987-10-20 | |
US18605488A | 1988-04-25 | 1988-04-25 | |
US23439088A | 1988-08-23 | 1988-08-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
LU91039I2 true LU91039I2 (en) | 2003-11-05 |
Family
ID=27492413
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU90951C LU90951I2 (en) | 1987-08-28 | 2002-09-04 | Eurifel rcp felv and its pharmaceutically acceptable derivatives |
LU91039C LU91039I2 (en) | 1987-08-28 | 2003-09-05 | Proteq flu and its pharmaceutically acceptable derivatives |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU90951C LU90951I2 (en) | 1987-08-28 | 2002-09-04 | Eurifel rcp felv and its pharmaceutically acceptable derivatives |
Country Status (17)
Country | Link |
---|---|
JP (3) | JP3348156B2 (en) |
KR (1) | KR970011149B1 (en) |
AR (1) | AR241939A1 (en) |
AT (1) | AT408549B (en) |
AU (2) | AU2427588A (en) |
BE (1) | BE1002134A5 (en) |
CH (2) | CH679934A5 (en) |
DE (4) | DE10399032I1 (en) |
DK (1) | DK175904B1 (en) |
FR (1) | FR2621487B1 (en) |
GB (1) | GB2217718B (en) |
IL (1) | IL87581A0 (en) |
IT (1) | IT1229484B (en) |
LU (2) | LU90951I2 (en) |
NL (4) | NL195051C (en) |
NZ (1) | NZ225970A (en) |
WO (1) | WO1989003429A1 (en) |
Families Citing this family (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5338683A (en) * | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US5505941A (en) * | 1981-12-24 | 1996-04-09 | Health Research, Inc. | Recombinant avipox virus and method to induce an immune response |
US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
DE10399032I1 (en) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Recombinant viruses. |
US5286639A (en) * | 1987-09-16 | 1994-02-15 | Nippon Zeon Co., Ltd. | Recombinant avipoxvirus |
DE3813093A1 (en) * | 1988-04-19 | 1989-11-09 | Immuno Ag | RECOMBINANT PLASMIDE, METHOD FOR PRODUCING A RECOMBINANT AVIPOX VIRUS, RECOMBINANT AVIPOX VIRUS, AND USE THEREOF |
US5631154A (en) * | 1988-06-10 | 1997-05-20 | Therion Biologics, Incorporated | Self assembled, defective, non-self-propagating lentivirus particles |
DE68912441T2 (en) * | 1988-06-24 | 1994-05-11 | British Tech Group | Nonessential chickenpox virus regions. |
US5093258A (en) * | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
CA2001001A1 (en) * | 1988-10-21 | 1990-04-21 | Matthew M. Binns | Fowlpox virus promoter |
US6248333B1 (en) | 1990-04-04 | 2001-06-19 | Health Research Inc. | Isolated nucleic acid sequence of equine herpesvirus type 1 glycoprotein D (EHV-1 gD) |
US5204243A (en) * | 1990-02-14 | 1993-04-20 | Health Research Incorporated | Recombinant poxvirus internal cores |
MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
US5514375A (en) * | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
FR2668064B1 (en) * | 1990-10-23 | 1994-12-16 | Transgene Sa | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF MALIGNANT TUMOR. |
US5756102A (en) * | 1990-11-20 | 1998-05-26 | Virogenetics Corporation | Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants |
US6309647B1 (en) | 1999-07-15 | 2001-10-30 | Aventis Pasteur | Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants |
IE68404B1 (en) * | 1990-11-20 | 1996-06-12 | Virogenetics Corp | Measles virus recombinant poxvirus vaccine |
US5503834A (en) * | 1990-11-20 | 1996-04-02 | Virogenetics Corporation | Measles virus recombinant poxvirus vaccine |
US5759841A (en) * | 1990-11-20 | 1998-06-02 | Virogenetics Corporation | Immunological composition of measles virus utilizing recombinant poxvirus |
US5338679A (en) * | 1991-01-08 | 1994-08-16 | Her Majesty The Queen In Right Of Canada, As Represented By National Research Council Canada And Forestry Canada | Vertebrate poxvoris expression vector under the control of entomopoxvirus spheroidin gene promoter |
US5766598A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products |
AU672581B2 (en) * | 1991-03-07 | 1996-10-10 | Virogenetics Corporation | Immunodeficiency virus recombinant poxvirus vaccine |
JP3602530B2 (en) * | 1991-03-07 | 2004-12-15 | ヴァイロジェネティクス コーポレイション | Genetically engineered vaccine strain |
US5863542A (en) * | 1991-03-07 | 1999-01-26 | Virogenetics Corporation | Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts |
US5756101A (en) * | 1991-07-01 | 1998-05-26 | Pasteur Merieux Serums Et Vaccins | Malaria recombinant poxvirus |
US5766597A (en) * | 1991-03-07 | 1998-06-16 | Virogenetics Corporation | Malaria recombinant poxviruses |
EP0575544A4 (en) * | 1991-03-20 | 1997-05-21 | Virogenetics Corp | Malaria recombinant poxvirus vaccine |
AU670538B2 (en) * | 1991-07-26 | 1996-07-25 | Virogenetics Corporation | Infectious bursal disease virus recombinant poxvirus vaccine |
DK0538496T3 (en) * | 1991-08-26 | 2004-02-23 | Baxter Healthcare Sa | Recombinant poultry pox virus with intact FPV tk gene |
US5443831A (en) * | 1991-10-29 | 1995-08-22 | University Of Delaware | Gene encoding glycoprotein B of Infectious Laryngotracheitis Virus |
US6328975B1 (en) | 1992-01-13 | 2001-12-11 | Syntro Corporation | Recombinant swinepox virus |
US6127163A (en) * | 1992-01-13 | 2000-10-03 | Syntro Corporation | Recombinant swinepox virus |
EP0623172B1 (en) * | 1992-01-13 | 2004-12-29 | Virogenetics Corporation | Marek's disease virus recombinant vaccinia virus vaccine |
US6497882B1 (en) | 1992-01-13 | 2002-12-24 | Syntro Corporation | Recombinant swinepox virus |
US6033904A (en) * | 1992-01-13 | 2000-03-07 | Syntro Corporation | Recombinant swinepox virus |
US5869312A (en) * | 1992-01-13 | 1999-02-09 | Syntro Corporation | Recombinant swinepox virus |
US6251403B1 (en) | 1992-01-13 | 2001-06-26 | Syntro Corporation | Recombinant swinepox virus |
WO1994006921A1 (en) * | 1992-09-21 | 1994-03-31 | Viagene, Inc. | Recombinant retroviral vector against felv and/or fiv |
WO1994019014A1 (en) * | 1993-02-26 | 1994-09-01 | Syntro Corporation | Recombinant fowlpox virus s-fpv-043 and uses thereof |
US6136318A (en) * | 1993-02-26 | 2000-10-24 | Cochran; Mark D. | Recombinant fowlpox viruses and uses thereof |
US5925358A (en) * | 1993-02-26 | 1999-07-20 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof |
AU727278B2 (en) * | 1993-02-26 | 2000-12-07 | Syntro Corporation | Recombinant fowlpox viruses and uses thereof II |
US5496731A (en) * | 1993-03-25 | 1996-03-05 | Xu; Hong-Ji | Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy |
US5843742A (en) * | 1994-12-16 | 1998-12-01 | Avigen Incorporated | Adeno-associated derived vector systems for gene delivery and integration into target cells |
EP0753581A1 (en) | 1995-07-10 | 1997-01-15 | Immuno Ag | Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines |
US5858373A (en) * | 1995-12-01 | 1999-01-12 | Virogenetics Corporation | Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them |
AU731860B2 (en) | 1996-07-25 | 2001-04-05 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant pox virus for immunization against tumor-associated antigens |
US6106825A (en) * | 1997-05-07 | 2000-08-22 | University Of Florida | Entomopoxvirus-vertebrate gene delivery vector and method |
AU3910097A (en) * | 1997-08-05 | 1999-03-01 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Live recombinant vaccine comprising inefficiently or non-replicating vir us |
US6248582B1 (en) * | 1997-10-08 | 2001-06-19 | Imran Khan | Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV |
JPH11165762A (en) | 1997-12-01 | 1999-06-22 | Lintec Corp | Cover tape for carrying chip body and sealing structure |
US20020147143A1 (en) | 1998-03-18 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of lung cancer |
US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
WO2000039302A2 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Improved expression of hiv polypeptides and production of virus-like particles |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
AU5771500A (en) | 1999-06-28 | 2001-01-31 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
AU2001256156B2 (en) | 2000-02-23 | 2006-01-05 | Smithkline Beecham Biologicals S.A. | Novel compounds |
JP2004513615A (en) | 2000-06-28 | 2004-05-13 | コリクサ コーポレイション | Compositions and methods for treatment and diagnosis of lung cancer |
US20030021766A1 (en) | 2001-01-12 | 2003-01-30 | Michael Vajdy | Nucleic acid mucosal immunization |
US6942864B2 (en) * | 2001-03-08 | 2005-09-13 | Akzo Nobel N.V. | Leporipox-based vector vaccines |
JP4499311B2 (en) * | 2001-04-27 | 2010-07-07 | シャープ株式会社 | Broadcast receiving terminal |
EP1988097A1 (en) | 2001-05-09 | 2008-11-05 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
EP2280074A3 (en) | 2001-07-05 | 2011-06-22 | Novartis Vaccines and Diagnostics, Inc. | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
US7211659B2 (en) | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
EP2224012B1 (en) | 2001-12-17 | 2013-01-30 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
RU2389732C2 (en) | 2003-01-06 | 2010-05-20 | Корикса Корпорейшн | Certain aminoalkyl glucosaminide phospahte derivatives and use thereof |
US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
CA2525825A1 (en) | 2003-05-15 | 2005-01-27 | Chiron Corporation | Hiv polynucleotides and polypeptides derived from botswana mj4 |
US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
CA2983954C (en) | 2004-09-22 | 2019-09-17 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
ES2514316T3 (en) | 2005-11-22 | 2014-10-28 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and Sapovirus virus-like particles (VLPs) |
WO2007120368A2 (en) | 2006-01-09 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
EP2441493B1 (en) | 2006-03-14 | 2014-05-07 | Oregon Health and Science University | Methods for producing an immune response to tuberculosis |
DK2918598T3 (en) | 2007-02-28 | 2019-04-29 | The Govt Of U S A As Represented By The Secretary Of The Dept Of Health And Human Services | Brachyury polypeptides and methods of use |
ES2662030T3 (en) | 2007-10-15 | 2018-04-05 | Admedus Vaccines Pty Limited | Construction system and uses for it |
US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
CN105056229A (en) | 2009-01-05 | 2015-11-18 | 埃皮托吉尼西斯股份有限公司 | Adjuvant compositions and methods of use |
US8664183B2 (en) | 2009-02-27 | 2014-03-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | SPANX-B polypeptides and their use |
CN102713629B (en) | 2009-11-20 | 2016-02-24 | 俄勒冈健康科学大学 | Method for detecting Mycobacterium tuberculosis infection |
WO2011106705A2 (en) | 2010-02-26 | 2011-09-01 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Dna-protein vaccination protocols |
US9795658B2 (en) | 2010-04-20 | 2017-10-24 | Admedus Vaccines Pty Ltd | Expression system for modulating an immune response |
US9428565B2 (en) | 2011-01-31 | 2016-08-30 | The General Hospital Corporation | Treatment and bioluminescent visualization using multimodal TRAIL molecules |
WO2012151272A2 (en) | 2011-05-02 | 2012-11-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
EP2723365A1 (en) | 2011-06-21 | 2014-04-30 | Oncofactor Corporation | Compositions and methods for the therapy and diagnosis of cancer |
AU2012272652B2 (en) | 2011-06-24 | 2017-06-01 | Epitogenesis Inc. | Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
US20150004144A1 (en) | 2011-12-02 | 2015-01-01 | The General Hospital Corporation | Differentiation into brown adipocytes |
US9605074B2 (en) | 2012-08-30 | 2017-03-28 | The General Hospital Corporation | Multifunctional nanobodies for treating cancer |
WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
CA3182572A1 (en) | 2013-04-17 | 2014-10-23 | Genzyme Corporation | Use of an il17 inhibitor for treating and preventing macular degeneration |
EP3010522B1 (en) | 2013-05-21 | 2021-01-20 | President and Fellows of Harvard College | Engineered heme-binding compositions and uses thereof |
CA2930693A1 (en) | 2013-11-15 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior Unversity | Methods of treating heart failure with agonists of hypocretin receptor 2 |
SG11201606101WA (en) | 2014-02-06 | 2016-08-30 | Genzyme Corp | Compositions and methods for treating and preventing macular degeneration |
JP7095990B2 (en) | 2014-09-18 | 2022-07-05 | シーダーズ-サイナイ メディカル センター | Compositions and Methods for Treating Fibrosis |
EP3270897A4 (en) | 2015-03-20 | 2018-12-05 | The Regents Of The University Of Michigan | Immunogenic compositions for use in vaccination against bordetella |
US20180112006A1 (en) | 2015-04-17 | 2018-04-26 | The General Hospital Corporation | Agents, systems and methods for treating cancer |
CN114366802A (en) | 2015-04-22 | 2022-04-19 | 西达-赛奈医疗中心 | Enterally delivered bitter oligopeptides for the treatment of type 2 diabetes |
US20180346520A1 (en) | 2015-05-13 | 2018-12-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And | Methods and compositions for inducing an immune response using conserved element constructs |
WO2016196366A1 (en) | 2015-05-29 | 2016-12-08 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Extension of replicative lifespan in diseases of premature aging using p53 isoforms |
US10550379B2 (en) | 2015-06-29 | 2020-02-04 | The Board Of Trustees Of The Leland Stanford Junior University | Degron fusion constructs and methods for controlling protein production |
JP7110108B2 (en) | 2015-12-09 | 2022-08-01 | ジンガン メディスン(オーストラリア) プロプライアタリー リミティド | Therapeutic immunomodulatory compositions |
EP3472193A4 (en) | 2016-06-20 | 2020-01-08 | The Board of Trustees of the Leland Stanford Junior University | CIRCULAR RNA AND THEIR USE IN IMMUNO MODULATION |
US11285191B2 (en) | 2016-07-26 | 2022-03-29 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Immunostimulatory compositions and uses therefor |
WO2019055878A2 (en) | 2017-09-15 | 2019-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Multiplex production and barcoding of genetically engineered cells |
US10917454B1 (en) | 2019-08-01 | 2021-02-09 | Rohde & Schwarz Gmbh & Co. Kg | System and method for ATC voice quality assurance |
US20250011787A1 (en) | 2021-10-21 | 2025-01-09 | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads | Retroelement-generated transcription factor decoys |
WO2023077147A2 (en) | 2021-11-01 | 2023-05-04 | Pellis Therapeutics, Inc. | T-cell vaccines for patients with reduced humoral immunity |
CA3237482A1 (en) | 2021-11-03 | 2023-05-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Precise genome editing using retrons |
WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
WO2023183588A1 (en) | 2022-03-25 | 2023-09-28 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Methods of assessing engineered retron activity, and uses thereof |
US20250215422A1 (en) | 2022-03-25 | 2025-07-03 | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads | RT-DNA Fidelity and Retron Genome Editing |
US20250215458A1 (en) | 2022-03-25 | 2025-07-03 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David | Production of reverse transcribed DNA (RT-DNA) using a retron reverse transcriptase from exogenous RNA |
WO2024020346A2 (en) | 2022-07-18 | 2024-01-25 | Renagade Therapeutics Management Inc. | Gene editing components, systems, and methods of use |
WO2024044673A1 (en) | 2022-08-24 | 2024-02-29 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Dual cut retron editors for genomic insertions and deletions |
WO2024044723A1 (en) | 2022-08-25 | 2024-02-29 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
WO2024233791A1 (en) | 2023-05-11 | 2024-11-14 | Seelos Therapeutics, Inc. | Methods of treating neurodegenerative disorders |
WO2025081042A1 (en) | 2023-10-12 | 2025-04-17 | Renagade Therapeutics Management Inc. | Nickase-retron template-based precision editing system and methods of use |
WO2025155753A2 (en) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Improved gene editing system, guides, and methods |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK489481A (en) * | 1980-11-10 | 1982-05-11 | Searle & Co | PLASMID VECTOR AND METHOD OF PRODUCING THEREOF |
US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
WO1984002077A1 (en) * | 1982-11-30 | 1984-06-07 | Us Health | Process for producing poxvirus recombinants for expression of foreign genes |
FR2563434B1 (en) * | 1984-04-25 | 1986-07-25 | Transgene Sa | Rabies vaccine and process for its preparation |
EP0190254A4 (en) * | 1984-07-05 | 1987-03-09 | Genex Corp | Cloned gene and method for making and using the same. |
DD235669A1 (en) * | 1985-03-26 | 1986-05-14 | Akad Wissenschaften Ddr | METHOD FOR PRODUCING A BLV-CODED HUEL PROTEIN |
US5032520A (en) * | 1985-03-29 | 1991-07-16 | National Research Development Corporation | DNA sequences encoding infectious bronchitis virus spike protein |
AU6170486A (en) * | 1985-08-23 | 1987-02-26 | Advanced Genetics Research Institute | Defective viral vaccines |
AU607399B2 (en) * | 1985-09-09 | 1991-03-07 | Cetus Corporation | Infectious recombinant virus vaccine for feline leukemia |
GR862412B (en) * | 1985-09-25 | 1987-01-23 | Oncogen | Vaccines and immuinoassays for acquired immune deficiency syndrome |
AU602875B2 (en) * | 1985-12-18 | 1990-11-01 | British Technology Group Limited | Newcastle disease virus gene clones |
AU8075787A (en) * | 1986-09-22 | 1988-04-07 | Australian National University, The | Recombinant poxviruses |
WO1988002022A1 (en) * | 1986-09-22 | 1988-03-24 | Commonwealth Scientific And Industrial Research Or | Recombinant poxviruses |
EP0261940A3 (en) * | 1986-09-23 | 1989-07-05 | Applied Biotechnology, Inc. | Pseudorabies vaccines and dna vectors for recombination with pox viruses |
AU605567B2 (en) * | 1987-03-11 | 1991-01-17 | Nippon Zeon Co., Ltd. | Recombinant avipoxvirus |
DE10399032I1 (en) * | 1987-08-28 | 2004-01-29 | Health Research Inc | Recombinant viruses. |
GB8724885D0 (en) * | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
FR2632863B2 (en) * | 1987-10-29 | 1990-08-31 | Transgene Sa | RECOMBINANT FOWLPOX VIRUS AND VACCINES DERIVED FROM SUCH VIRUSES |
DE68912441T2 (en) * | 1988-06-24 | 1994-05-11 | British Tech Group | Nonessential chickenpox virus regions. |
AU625584B2 (en) * | 1989-03-08 | 1992-07-16 | Health Research Inc. | Recombinant poxvirus host selection system |
BR9106879A (en) * | 1990-09-25 | 1993-07-20 | Cantab Pharma Res | MUTUANT NON RETROVIRAL VIRUS, USE OF THE SAME, VACCINE AND PROCESS OF MANUFACTURING MUTANT UMVIRUS |
-
1987
- 1987-08-24 DE DE2003199032 patent/DE10399032I1/en active Pending
- 1987-08-24 DE DE2003199031 patent/DE10399031I1/en active Pending
-
1988
- 1988-08-24 JP JP50771588A patent/JP3348156B2/en not_active Expired - Lifetime
- 1988-08-24 CH CH1444/91A patent/CH679934A5/de not_active IP Right Cessation
- 1988-08-24 AT AT0900788A patent/AT408549B/en not_active IP Right Cessation
- 1988-08-24 GB GB8908921A patent/GB2217718B/en not_active Expired - Lifetime
- 1988-08-24 AU AU24275/88A patent/AU2427588A/en not_active Abandoned
- 1988-08-24 DE DE3890874A patent/DE3890874C5/en not_active Expired - Lifetime
- 1988-08-24 KR KR1019890700753A patent/KR970011149B1/en not_active Expired - Lifetime
- 1988-08-24 WO PCT/US1988/002816 patent/WO1989003429A1/en active Application Filing
- 1988-08-24 NL NL8820679A patent/NL195051C/en not_active IP Right Cessation
- 1988-08-24 CH CH1652/89A patent/CH679933A5/de not_active IP Right Cessation
- 1988-08-24 DE DE2002199049 patent/DE10299049I1/en active Pending
- 1988-08-28 IL IL87581A patent/IL87581A0/en not_active IP Right Cessation
- 1988-08-29 NZ NZ225970A patent/NZ225970A/en unknown
- 1988-08-29 BE BE8800978A patent/BE1002134A5/en not_active IP Right Cessation
- 1988-08-29 FR FR888811334A patent/FR2621487B1/en not_active Expired - Lifetime
- 1988-08-29 IT IT8821772A patent/IT1229484B/en active
- 1988-08-29 AR AR88311787A patent/AR241939A1/en active
-
1989
- 1989-04-27 DK DK198902036A patent/DK175904B1/en active Protection Beyond IP Right Term
-
1995
- 1995-04-05 AU AU16288/95A patent/AU690210B2/en not_active Expired
-
2001
- 2001-10-09 JP JP2001311076A patent/JP2002186494A/en active Pending
-
2002
- 2002-03-15 JP JP2002071416A patent/JP3826055B2/en not_active Expired - Lifetime
- 2002-09-04 LU LU90951C patent/LU90951I2/en unknown
-
2003
- 2003-07-09 NL NL300130C patent/NL300130I2/en unknown
- 2003-09-05 LU LU91039C patent/LU91039I2/en unknown
- 2003-11-25 NL NL300139C patent/NL300139I1/en unknown
- 2003-11-25 NL NL300138C patent/NL300138I2/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU91039I2 (en) | Proteq flu and its pharmaceutically acceptable derivatives | |
LU90829I2 (en) | Tepoxalin-zubrin and its pharmaceutically acceptable derivatives | |
LU91205I2 (en) | Ciclesonide and its pharmaceutically acceptable derivatives (alvesco) | |
LU90736I2 (en) | Agenerase-amprenavir and its pharmaceutically acceptable derivatives | |
LU88736I2 (en) | Cefquinome and its pharmaceutically acceptable derivatives (COBACTAN) | |
LU90219I2 (en) | Tolcapone and its pharmaceutically acceptable derivatives (TASMAR) | |
LU88750I2 (en) | VENLAFAXINE and its pharmaceutically acceptable derivatives | |
LU90769I2 (en) | Capecitabine and its pharmaceutically acceptable derivatives (xeloda) | |
LU90069I2 (en) | Lercanidipine and its pharmaceutically acceptable salts and derivatives (Zanidip) | |
LU90484I2 (en) | Novorapid - insulin aspart and its pharmaceutically acceptable salts and derivatives | |
LU90037I2 (en) | Konakion and its pharmaceutically acceptable derivatives | |
NL300136I2 (en) | Pharmacologically active catechol derivatives and their compositions. | |
FI895821A7 (en) | Pharmaceutically active CNS compounds | |
LU91197I2 (en) | Azoxystrobin and folpel and their pharmaceutically acceptable derivatives (QUADRIS MAX). | |
KR910700249A (en) | New therapeutically active compounds and methods for their preparation | |
DK40788A (en) | PHENYL-SUBSTITUTED PURINO DERIVATIVES | |
LU91189I2 (en) | Atazanavir sulphate and its pharmaceutically acceptable derivatives (REYATAZ) | |
LU90844I2 (en) | es Riamet and its pharmaceutically acceptable derivatives | |
LU91147I2 (en) | Pemetrexed and its pharmaceutically acceptable salts. | |
LU88790I2 (en) | Moxidectin and its pharmaceutically acceptable derivatives | |
LU88843I2 (en) | Ropivacaine and its pharmaceutically acceptable derivatives (Naropine R) | |
TR24895A (en) | DERIVATIVES OF PIRIMID, ITS ADMINISTRATION AND USE | |
IT1217573B (en) | PHARMACOLOGICALLY ACTIVE SUBSTITUTED BENZAMIDS | |
DK435688D0 (en) | PHARMACEUTICAL AGENTS | |
FI883867A7 (en) | Use of 2-pyrimidinyl-1-piperazine derivatives. |